Cullen Frost Bankers Inc. Acquires 78 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Cullen Frost Bankers Inc. grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,717 shares of the biopharmaceutical company’s stock after acquiring an additional 78 shares during the period. Cullen Frost Bankers Inc.’s holdings in Alnylam Pharmaceuticals were worth $2,894,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ALNY. Park Square Financial Group LLC bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at about $28,000. Whipplewood Advisors LLC grew its holdings in shares of Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 71 shares during the period. Bessemer Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 69 shares in the last quarter. Colonial Trust Co SC purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $35,000. Finally, Washington Trust Advisors Inc. grew its position in shares of Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 61 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of the firm’s stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the transaction, the chief executive officer owned 48,948 shares of the company’s stock, valued at approximately $14,978,088. This trade represents a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ALNY has been the subject of several analyst reports. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, July 5th. Royal Bank Of Canada boosted their price target on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an “outperform” rating in a research report on Friday, March 21st. Redburn Atlantic began coverage on Alnylam Pharmaceuticals in a research report on Monday, March 31st. They issued a “buy” rating and a $353.00 target price on the stock. Morgan Stanley dropped their price target on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating on the stock in a research report on Friday, April 11th. Finally, BMO Capital Markets upped their price objective on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 24th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-two have issued a buy rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $346.13.

Alnylam Pharmaceuticals Trading Up 0.6%

Shares of ALNY stock opened at $324.69 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $333.70. The firm has a fifty day moving average price of $305.09 and a 200-day moving average price of $270.94. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98. The company has a market cap of $42.34 billion, a price-to-earnings ratio of -155.35 and a beta of 0.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The firm had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same quarter in the previous year, the company posted ($0.16) earnings per share. The business’s revenue for the quarter was up 20.2% on a year-over-year basis. As a group, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.